NDA 209884 · Novartis
Mayzent
Siponimod · Oral · Sphingosine 1-phosphate Receptor Modulator
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 26, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
17
4 Phase 3, 2 recruiting
FAERS reports
8,919
4,480 serious, 207 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2026.
MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Mechanism: Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which siponimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2022 Supplement 7 · Efficacy LetterLabel
- Mar 26, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
- MAYZENT · SIPONIMOD EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
- MAYZENT · SIPONIMOD EQ 0.25MG BASE · TABLET, ORAL · Prescription · TE AB
- MAYZENT · SIPONIMOD EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Siponimod" as an intervention, any sponsor and status, largest first.
- Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01665144 · 1,651 participants · Start Dec 20, 2012 · Primary completion Apr 29, 2016
Drug: BAF312; Placebo · For: Secondary Progressive Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Los Angeles, California · 290 sites in all
- Determinants of Warfarin MetabolismRecruiting
Hadassah Medical OrganizationAcademic, hospital or other
NCT00162474 · 1,000 participants (planned) · Start Sep 2003 · Primary completion Dec 2030
Drug: Warfarin; Phenytoin and 4 more · For: Healthy
Sites: Jerusalem, Israel
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00879658 · 297 participants · Start Mar 30, 2009 · Primary completion May 4, 2011
Drug: BAF312; Placebo · For: Relapsing-remitting Multiple Sclerosis
Sites: Cullman, Alabama; San Francisco, California; Centennial, Colorado · 72 sites in all
- Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01185821 · 185 participants · Start Aug 30, 2010 · Primary completion Oct 10, 2016
Drug: BAF312 · For: Relapsing Remitting Multiple Sclerosis
Sites: Miami, Florida; Pompano Beach, Florida; Tallahassee, Florida · 46 sites in all
- Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03623243 · 185 participants · Start Feb 14, 2019 · Primary completion Jul 6, 2022
Drug: Siponimod · For: Multiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Homewood, Alabama · 55 sites in all
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04926818 · 129 participants · Start Oct 5, 2021 · Primary completion Mar 25, 2026
Drug: Fingolimod; Ofatumumab and 1 more · For: Multiple Sclerosis (MS)
Sites: Little Rock, Arkansas; Los Angeles, California; Washington D.C., District of Columbia · 51 sites in all
- Repurposing Siponimod for Alzheimer's DiseasePivotal-lookingRecruiting
St. Joseph's Hospital and Medical Center, PhoenixAcademic, hospital or other
NCT06639282 · 105 participants (planned) · Start Aug 26, 2025 · Primary completion Oct 2029
Drug: Siponimod; Placebo · For: Alzheimer Disease; Mild Alzheimer Disease; MCI With Increased Risk for Alzheimer Disease and 1 more
Sites: Phoenix, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,002
- headache892
- dizziness674
- multiple sclerosis relapse548
- gait disturbance539
- fall519
- multiple sclerosis489
- nausea424
- drug ineffective422
- lymphocyte count decreased421
- product dose omission issue396
- urinary tract infection385
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 7 |
| 2019 | 906 |
| 2020 | 2,147 |
| 2021 | 1,975 |
| 2022 | 1,551 |
| 2023 | 1,266 |
| 2024 | 507 |
| 2025 | 351 |
| 2026 | 202 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mayzent (Siponimod)
2024 spending
$75.8M
Beneficiaries
850
6,850 claims
Per beneficiary
$89,232
$313.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $44,651,698 |
| 2021 | $64,271,201 |
| 2022 | $71,384,518 |
| 2023 | $79,550,294 |
| 2024 | $75,847,094 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, et al. · Lancet 2018 · Clinical Trial, Phase III, Multicenter Study
- Siponimod for multiple sclerosis.
Cao L, Li M, Yao L, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacogenetics of siponimod: A systematic review.
Díaz-Villamarín X, Piñar-Morales R, Barrero-Hernández FJ, et al. · Biomed Pharmacother 2022 · Systematic Review
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.
Ridley B, Minozzi S, Gonzalez-Lorenzo M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.